You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Harvard Business School
Baxter
Medtronic
Boehringer Ingelheim

Last Updated: November 29, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Tremelimumab

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Tremelimumab?

Tremelimumab is an investigational drug.

There have been 147 clinical trials for Tremelimumab. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and M.D. Anderson Cancer Center.

There are eighty-two US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Tremelimumab
TitleSponsorPhase
Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant TreatmentCatherine ShuPhase 2
Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner DesignAstraZenecaPhase 2
Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner DesignInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestPhase 2

See all Tremelimumab clinical trials

Clinical Trial Summary for Tremelimumab

Top disease conditions for Tremelimumab
Top clinical trial sponsors for Tremelimumab

See all Tremelimumab clinical trials

US Patents for Tremelimumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tremelimumab   Start Trial Immunoregulatory agents Flexus Biosciences, Inc. (Princeton, NJ)   Start Trial
Tremelimumab   Start Trial .beta.-glucan methods and compositions that affect the tumor microenvironment BIOTHERA, INC. (Eagan, MN)   Start Trial
Tremelimumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Tremelimumab   Start Trial Methods of using OX40 ligand encoding polynucleotides ModernaTX, Inc. (Cambridge, MA)   Start Trial
Tremelimumab   Start Trial Intralesional (Intratumoral) dinitrochlorobenzene and associated compounds coadministered with checkpoint inhibitors for cancer treatment including treatment of metastatic cutaneous cancers   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tremelimumab

Drugname Country Document Number Estimated Expiration Related US Patent
Tremelimumab Argentina 102536 2034-11-05   Start Trial
Tremelimumab Australia 2015342940 2034-11-05   Start Trial
Tremelimumab Brazil 112017008568 2034-11-05   Start Trial
Tremelimumab Canada 2964290 2034-11-05   Start Trial
Tremelimumab Chile 2017001124 2034-11-05   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Harvard Business School
Baxter
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.